Keymed Biosciences Inc (HKSE:02162) Share Price

Company Profile

Business description
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
Contact
No. 18 BioTown Middle Road
Building D2
Tianfu International BioTown, Chengdu
Sichuan610219
CHN
T: +86 2888610620
https://www.keymedbio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,258

Recommended

Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.

Shane Ponraj, CFA | 05 August 2025

Morningstar’s Greg Warren says Berkshire may have little choice but to take a hard look at this huge potential acquisition.

Joseph Taylor | 05 August 2025

A key provision of the new award is that Musk must remain in a senior leadership position at Tesla.

Seth Goldstein, CFA | 04 August 2025

Index	Last price	Change	% Change
All Ordinaries	9,018.20	96.20	1.08%
CAC 40	7,632.01	85.85	1.14%
DAX 40	23,757.69	331.72	1.42%
Dow JONES (US)	44,173.64	585.06	1.34%
FTSE 100	9,128.30	59.72	0.66%
HKSE	24,799.67	66.22	0.27%
NASDAQ	21,053.58	403.45	1.95%
Nikkei 225	40,549.93	259.23	0.64%
NZX 50 Index	12,857.29	173.25	1.37%
S&P 500	6,329.94	91.93	1.47%
S&P/ASX 200	8,760.80	97.10	1.12%
SSE Composite Index	3,602.13	18.82	0.53%